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Summary
Objective: To investigate the effect of the histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), on joint inﬂammation and cartilage
degeneration in a collagen antibody-induced arthritis (CAIA) mouse model.
Methods: CAIA mice were given daily subcutaneous injections of various concentrations of TSA (0, 0.5, 1.0, and 2.0 mg/kg) and various
parameters were monitored for 14 days. On Day 15, the hind paws were examined histologically. To investigate the effects of TSA on the
expressions of matrix metalloproteinase (MMP)-3, MMP-13, tissue inhibitor of MMP-1 (TIMP-1), and acetyl-H4 by chondrocytes, another group
of mice was sacriﬁced on Day 6. In vitro direct effect of TSA was examined by real-time PCR for mRNA of type II collagen, aggrecan, MMP-3,
and MMP-13 in murine chondrogenic ATDC5 cells after pro-inﬂammatory cytokine stimulation.
Results: In the TSA-treated group, clinical arthritis was signiﬁcantly ameliorated in a dose-dependent manner. The severity of synovial inﬂam-
mation and the cartilage destruction score were signiﬁcantly lower in the TSA 2.0 mg/kg group compared to the other TSA-treated groups. On
immunohistochemistry, the number of MMP-3 and MMP-13-positive chondrocytes was signiﬁcantly lower in the TSA 2.0 mg/kg group than in
the control group. In contrast, the number of TIMP-1-positive cells and acetyl-histone H4-positive cells was signiﬁcantly higher in the TSA
2.0 mg/kg group than in the control group. TSA suppressed interleukin 1-b and tumor necrosis factor-a-stimulated up-regulation of MMP-3,
but not MMP-13 mRNA expression by ATDC5.
Conclusion: The systemic administration of TSA ameliorated synovial inﬂammation in CAIA mice. Subsequently cartilage destruction was also
suppressed by TSA, at least in part, by modulating chondrocyte gene expression.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Rheumatoid arthritis (RA) is a systemic disease, character-
ized by multiple joint inﬂammation associated with synovial
hyperplasia, as well as concomitant bone and cartilage de-
struction. The high levels of pro-inﬂammatory cytokines and
proteases that are released from synovial tissue cause
changes in chondrocytemetabolism andmatrix degradation,
which lead to cartilage destruction1,2.There is an increasing1This work was supported by a Grant from the Japan Orthopae-
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723evidence that prompt anti-tumor necrosis factor (TNF)-a
therapy effectively decreases not only synovial inﬂammation,
but also boneandcartilagedestruction; however, these inhib-
itory effects are limited to certain patient populations3e5.
Recent reports suggest that the epigenetic regulation of
gene expressionmay be a novel therapeutic approach for ar-
thritis6. It has been previously shown in an animal arthritis
model that modiﬁcation of histone acetylation by histone
deacetylase (HDAC) inhibitors, such as trichostatin A (TSA)
or depsipeptide (FK228), can successfully ameliorate the
synovial inﬂammation via the up-regulation in synovial
ﬁbroblasts of cell cycle regulators, such as p16INK4a and
p21Cip1/WAF17,8. More recently, Jungel et al. demonstrated
that TSA sensitizes synovial ﬁbroblasts to tumor necrosis
factor-related apoptosis inducing ligand (TRAIL)-induced
apoptosis, which provides another mechanism for under-
standing theeffect thatHDAC inhibitors have in the regulation
of cell proliferation9. It has also been shown in mice that
CB
A
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struction via the suppression of osteoclastogenesis by induc-
ing INF-b10. However, there is not enough evidence to
determine whether HDAC inhibitors alter the gene expres-
sion of chondrocytes by modifying the chromatin structure.
Cartilage destruction in arthritis is mainly mediated by the
breakdown of cartilage extracellular matrix (ECM) by two
distinct proteases: the matrix metalloproteinases (MMPs)
and the aggrecanases11. Young et al. examined the effect
of HDAC inhibitors on chondrocyte expression of MMP or
aggrecanases in vitro and in an explant assay. They dem-
onstrated that HDAC inhibitors exhibit a chondro-protective
property by blocking the expression of pro-inﬂammatory
cytokine-induced MMP-1, MMP-13, and a disintegrin and
metalloproteinase with thrombospondin motifs (ADAMTS)
aggrecanases at the mRNA and protein levels12. However,
it is unclear whether the inhibitory effects that HDAC inhib-
itors have on chondrocyte protease expression correlate
in vivo with pathogenesis. Thus, in this study, the effect of
various amounts of TSA on cartilage destruction was
examined in a collagen antibody-induced arthritis (CAIA)
mouse model. The effects of TSA on chondrocyte protease
expression were examined by immunohistochemistry. To
address whether TSA affects chondrocyte function directly,
murine ATDC5 chondrogenic cells were stimulated by
pro-inﬂammatory cytokines, and the effect of TSA on chon-
drocyte gene expressions was examined by real-time poly-
merase chain reaction (PCR). The results of the current
study might provide further evidence that HDAC inhibitors,
by inhibiting the pathogenic process of cartilage degrada-
tion, can have a role in the treatment of arthritis.MethodsANIMALS, ARTHRITIS INDUCTION, AND TSA TREATMENTFig. 1. Arthritis induction in mice and the effects of TSA. (A) The ar-
thritis induction and TSA treatment protocol. Sampling 1: sections
for immunohistochemistry. Sampling 2: histological evaluation of ar-
thritis and cartilage destruction. (B) Severity of the clinical signs in
untreated (CAIA) and TSA-treated mice (see Methods for scoring
system). TSA treatment had a dose-dependent inhibitory effect
against CAIA. (C) Body weight changes by group. After the onsetTwenty-four, 6e7-week-old, male DBA/1 mice (Charles River Japan,
Yokohama, Japan) were used to evaluate the disease modifying activity of
TSA in vivo. All animal research was conducted in accordance with the
requirements of the Okayama University Animal Research Committee. The
mice were housed at the Laboratory Animal Center for Biochemical
Research, Okayama University Graduate School of Medicine and Dentistry,
under standard diurnal conditions, fed a standard commercial diet, and given
tap water ad libitum. Arthritis was induced by an arthritogenic cocktail of four
monoclonal antibodies (mAbs) to type II collagen (Chondrex, Redmond, WA,
USA) combined with lipopolysaccharide (LPS) simulation according to Tera-
to’s method13,14. The mice were injected intraperitoneally with 2 mg of mAb
on Day 0 and Day 1 (4 mg total), followed by intraperitoneal (i.p.) injection of
50 mg of LPS on Day 2. After the onset of clinically detectable arthritis, the
treatment group (n¼ 18) was given daily hypodermic injections of TSA
(SigmaeAldrich, Oakville, Ontario, Canada) (0.5, 1.0, or 2.0 mg/kg of body
weight in the TSA 0.5, TSA 1.0, TSA 2.0 groups, respectively) until the
end of the experiment (Day 14). The TSA was dissolved in dimethyl sulfoxide
(DMSO) and then diluted with phosphate buffer saline (PBS) to the ﬁnal con-
centration. Control mice (n¼ 6) were injected with 0.1% DMSO. In addition to
these groups, ﬁve CAIA mice treated with 2.0 mg/kg of TSA and ﬁve control
mice were sacriﬁced on Day 6 for immunohistochemical analysis of articular
cartilage [Fig. 1(A)].of clinical arthritis, all mice lost a small amount of weight. No signif-
icant differences were observed among the groups. Data are ex-
pressed as the means (symbols) S.E.M. (error bars) (*P< 0.05CLINICAL EVALUATION OF ARTHRITISand **P< 0.001 by Bonferroni/Dunn analysis).
The mice were monitored for the development of arthritis every day after
the ﬁrst mAb injection. According to the method of Terato et al.13, each limb
was graded individually on a scale of 0e4, where 0¼ normal, 1¼mild but def-
inite redness and swelling of the ankle or wrist or redness and swelling of any
degree in any single digit, 2¼moderate to severe redness and swelling of the
ankle or wrist, 3¼ redness and swelling of the entire foot including the digits,
and 4¼maximally inﬂamed limb, with involvement of multiple joints. The
maximum cumulative clinical arthritis score for each mouse was 16.HISTOLOGIC ANALYSIS OF HIND PAWSOnDay 15, themicewere euthanized by the systemic perfusion of 4%para-
formaldehyde in 0.1 M PBS under general anesthesia. The limbs weredissected and ﬁxed in the same solution for 24 h. The samples were decalci-
ﬁed in 0.3 M ethylenediaminetetraacetic acid (EDTA) (pH 7.5) for 7e10 days,
divided into two blocks along the sagittal plane, dehydrated in a graded etha-
nol series, and embedded in parafﬁn. Standard sagittal sections measuring
4.5 mm were prepared and stained with hematoxylin and eosin. Histologic ex-
aminations for synovial inﬂammation, as well as bone and cartilage damage,
were performed independently by two of the authors (KN and YN). The sec-
tions were graded according to the system described by Sancho et al.15,
where grade 0¼ no inﬂammation, grade 1¼ slight thickening of the synovial
cell layer and/or some inﬂammatory cells in the sublining, grade 2¼ thickening
of the synovial lining, inﬁltration of the sublining, and localized cartilage
725Osteoarthritis and Cartilage Vol. 16, No. 6erosions, and grade 3¼ inﬁltration in the synovial space, pannus formation,
cartilage destruction, and bone erosion. Cartilage destruction was graded
according to the system described by Kamekura et al.16, where grade 0¼ no
apparent changes, grade 1¼ loss of superﬁcial zone in articular cartilage,
grade 2¼ defects limited above the tidemark, grade 3¼ defects extending
to the calciﬁed cartilage, and grade 4¼ exposure of the subchondral bone.IMMUNOHISTOCHEMISTRY OF ARTICULAR CARTILAGEImmunohistochemistry was performed as previously described using the
parafﬁn sections of paw joint tissues obtained from control and TSA 2.0 group
mice (n¼ 5 each) on Day 614. Immunostaining for MMP-3, MMP-13, tissue
inhibitor of MMP-1 (TIMP-1), and acetyl-histone H4 was performed on sec-
tions obtained from the hind paw joints of the mice on Day 6. For MMP-3,
MMP-13, and TIMP-1 immunohistochemistry, deparafﬁnized and dehydrated
sections were pretreated by boiling in 10 mmol/l of citrate buffer (pH 6) for
10 min, and then allowed to slowly cool to room temperature. To detect
acetyl-histone H4, the slides were treated with 1 mg/ml of hyaluronidase
(Streptomyces Hyalurolyticus, Seikagaku Co., Tokyo, Japan) for 2 h at room
temperature. Endogenous peroxidase was blocked by immersing the
specimens in 0.3% H2O2 in PBS; the specimens were then treated with
10% normal goat serum. Rabbit polyclonal anti-MMP-3 antibody (10 mg/ml;
SigmaeAldrich), anti-MMP-13 antibody (20 mg/ml; SigmaeAldrich), anti-
TIMP-1 antibody (30 mg/ml; SigmaeAldrich), and anti-acetyl-histone H4 anti-
body (30 mg/ml; Cell Signaling Technology, Beverly, MA, USA) were used
as the primary antibodies; they were incubated with the specimens at room
temperature over night and then washed with PBS. Then, they were incubated
with biotinylated goat anti-rabbit antibody (Vector Laboratories, Burlingame,
CA, USA) (7.5 mg/ml) at room temperature for 30 min (for MMP-3, MMP-13,
and TIMP-1) or for 1 h (for acetyl-histone H4). Tissue sections were visualized
by diaminobenzidine (DAB) and counterstained by methyl green or eosin.
Stained sections incubated with normal rabbit non-immune serum or those
incubated without primary antibodies were used as negative controls. The
immunopositive cells were counted individually in three different areas under
a light microscope (magniﬁcation: 400); the number of cells was then aver-
aged. The percentage of immunopositive chondrocytes was determined by
dividing the number of positive chondrocytes by the total number of chondro-
cytes in all cartilage layers within the ﬁeld.CELL CULTUREMurine ATDC5 chondrogenic cells were obtained from the Riken Cell Bank
(Tsukuba, Japan). Cells were grown in a standard medium of Dulbecco’s
modiﬁed Eagle’s medium (DMEM)/F-12 containing 5% fetal bovine serum
(FBS) at 37C under 5% CO2. The medium was replaced every other day.CONVENTIONAL REVERSE TRANSCRIPTION POLYMERASE
CHAIN REACTION (RT-PCR) AND REAL-TIME PCR FOR
DETECTION OF mRNA OF ECM PROTEINS AND MMPsATDC5 cells were seeded at a density of 106 cells/well into 6-well dishes,
starved in serum-free medium for 24 h, stimulated with both TNF-a (1 ng/ml)
and interleukin (IL)-1b (10 ng/ml) and incubated with or without 2 mM of TSA
under an atmosphere of 5% CO2 for 6 h. Total RNA was isolated from cul-
tured cells with Isogen reagent (Nippon Gene, Toyama, Japan), and re-
verse-transcribed to cDNA using Rever Tra Ace (Toyobo, Tokyo, Japan).
Conventional RT-PCR was performed to conﬁrm the alteration of type II
collagen (Col2a1) and aggrecan expression at the mRNA level. The cDNAs
underwent PCR ampliﬁcation in the presence of 10 pmol of each speciﬁc
primer, 200 mM deoxyribonucleotide triphosphates, and 0.5 U Taq DNA poly-
merase (Qiagen K.K., Tokyo, Japan). PCR comprised 20 cycles for b-actin,
35 cycles for Col2a1, and 40 cycles for aggrecan, with denaturing at 94C for
30 s, annealing at 60C for 30 s, and extension at 72C for 40 s in each cycle
using an automated thermal cycler (PerkineElmer Applied Biosystems, Fos-
ter, CA, USA). PCR products were analyzed by agarose gel electrophoresis
and visualized with ethidium bromide under UV light.
For quantitative analysis of MMP-3 and MMP-13 expression, real-time
PCR reactions were performed on a LightCycler instrument (Roche Diagnos-
tics, Mannheim, Germany) using a LightCycler FastStart DNA Master SYBR
Green I kit (Roche Molecular Biochemicals, Mannheim, Germany) as recom-
mended by the manufacturer. The ﬁnal expression value was calculated by
dividing the level of target mRNA expression by the level of b-actin mRNA ex-
pression, and expressed as fold change over unstimulated control in ﬁgures.
The primer sequences of the Col2a1, aggrecan, MMP-3, -13 (Greiner bio-
one, Tokyo, Japan) and b-actin (SigmaeAldrich) used were as follows: for
Col2a1, 50-ACGAAGCGGCTGGCAACCTCA-30 (forward) and 50-CCCTCG
GCCCTCATCTCTACATCA-30 (reverse); for aggrecan, 50-GTGAGGACCT
GGTAGTGCGAGTGA-30 (forward) and 50-GAGCCTGGGCGATAGTGGAA
TATA-30 (reverse): for MMP-3, 50-ATGAAAATGAAGGGTCTTCCGG-30
(forward) and 50-GCAGAAGCTCCATACCAGCA-30 (reverse); for MMP-13,
50-ATGCATTCAGCTATCCTGGCCA-30 (forward) and 50-AAGATTGCATTTCTCGGAGCCTG-30 (reverse) and for b-actin, 50-GGGGTGTTGAAGGTC
TCAAA-30 (forward) and 50-GATCTGGCACCACACCTTCT-30 (reverse).STATISTICAL ANALYSISThe statistical signiﬁcance of the differences between the groups was an-
alyzed using the Bonferroni/Dunn test for the analysis of clinical scores and
the non-parametric ManneWhitney U test for the histological, immunohisto-
chemical and in vitro analysis. Differences were considered statistically sig-
niﬁcant when the P value was equal to or less than 0.05.ResultsAMELIORATION OF JOINT PATHOLOGY AFTER
TSA TREATMENT IN CAIA MICEClinically apparent arthritis developed at Day 4 in all CAIA
mice, with marked swelling or redness of the joints of the
limbs. The arthritis in the control mice with CAIA (n¼ 6) pro-
gressed rapidly and markedly. The clinical active arthritis
score peaked on Day 6, with scores (meanSD [standard
deviation]) of 15.0 1.1 in the control group and 13.8 1.4
in the TSA 0.5 group. In contrast, the arthritis score was sig-
niﬁcantly less in the mice treated with daily subcutaneous
(s.c.) injections of TSA 1.0 mg/kg/day (12.8 2.1) and
TSA 2.0 mg/kg/day (10.0 3.1) (P< 0.001). The clinical ar-
thritis scores were signiﬁcantly lower in these mice, and
continued to decrease until the end of observation. On
Day 14, the clinical arthritis scores were 11.7 2.9,
10.8 2.3, 8.1 3.2, and 5.7 2.7 in the control, TSA
0.5, TSA 1.0, and the TSA 2.0 groups, respectively. Statis-
tical analysis showed that TSA decreased the clinical arthri-
tis in a dose-dependent manner [Fig. 1(B)].
The in vivo toxicity of TSA was assessed by daily moni-
toring of body weight, food intake, and behavior of the
mice in the treatment and control groups. All mice survived
the treatment period. On Day 14, there were no signiﬁcant
differences in the body weights among the four groups of
mice [Fig. 1(C)].HISTOLOGIC ASSESSMENT OF THE SEVERITY OF JOINT
INFLAMMATION AND CARTILAGE DESTRUCTIONSections of paw joint tissues obtained from the control
group showed marked pathologic changes, including
synovial hyperplasia, with a large number of inﬁltrating
inﬂammatory cells, extensive pannus formation at the
cartilageebone junction, and severe cartilage destruction.
The pathology of paw joint sections obtained from the treat-
ment groups was less severe with no to mild inﬂammation.
The mean synovial inﬂammation score (grades SD) were
3.0 0.3, 2.8 0.6, 2.2 0.8, and 1.4 0.9 in the control,
TSA 0.5, TSA 1.0, and TSA 2.0 groups, respectively. Syno-
vial inﬂammation was signiﬁcantly less severe in the TSA
1.0 and TSA 2.0 groups than in the other groups
(P< 0.05) (Fig. 2).
The cartilage destruction score developed by Kamekura
et al. was used to evaluate the extent of cartilage destruc-
tion in each mouse. The cartilage destruction scores
(meanSD) were 3.6 0.5, 3.1 0.7, 2.6 0.7, and
1.5 0.5 in the control, TSA 0.5, TSA 1.0 and TSA 2.0
groups, respectively (Fig. 3).IMMUNOHISTOCHEMISTRYTo evaluate the in vivo effects of TSA on the expression
of proteolytic enzymes in articular cartilage, immunohisto-
chemical analysis was performed using the hind paw joint
Fig. 2. Histological evaluation of arthritis. The severity of synovial inﬂammation was evaluated histologically in the specimens obtained on Day
15. Representative results showing the histological appearance of the hind paws are seen in the upper panel. The control group specimens
showed synovial hyperplasia, inﬂammatory cells proliferation, pannus formation, and bone destruction. Joint pathology was less severe in
TSA-treated mice. Arrows: synovial hyperplasia, asterisk: joint space. Original magniﬁcation: 100. The mean synovial inﬂammation score
was signiﬁcantly lower in the TSA 1.0 mg/kg and TSA 2.0 mg/kg groups than in the control group (n¼ 6). Error bars express S.E.M.
(*P< 0.01 and **P< 0.001 by Bonferroni/Dunn analysis).
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Fig. 3. Inhibition of cartilage destruction by TSA treatment. Representative photographs of each grade of cartilage destruction, grade 4 in the
control group, grade 3 in the TSA 0.5 mg/kg group, grade 2 in the TSA 1.0 mg/kg group, and grade 1 in the TSA 2.0 mg/kg group. Original
magniﬁcation: 400. The total cartilage destruction score was signiﬁcantly lower in the TSA 1.0 mg/kg and TSA 2.0 mg/kg groups than in the
control group (n¼ 6 each). Error bars express S.E.M. (*P< 0.001 by Bonferroni/Dunn analysis).
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728 Y. Nasu et al.: HDAC inhibitor on cartilage destructionspecimens obtained on Day 6 from the control and TSA 2.0
group mice. The Day 6 samples from both untreated and
treated mice showed synovial hyperplasia and inﬂammatory
cell inﬁltration, but the articular cartilage structure was
preserved.
Next, the endogenous MMP-3, MMP-13 and TIMP-1
levels in the articular cartilage chondrocytes were exam-
ined. Chondrocytes in inﬂammatory articular cartilage
were strongly stained for both MMP-3 and MMP-13. The
population of MMP-3-positive cells was signiﬁcantly lower
in the TSA-treated group than in the control group. There
were signiﬁcant differences in the population of MMP-13-
positive chondrocytes between the TSA 2.0 and control
groups. As well, the number of TIMP-1-positive chondro-
cytes was signiﬁcantly higher in the TSA 2.0 group than in
the control group (Fig. 4).
Chondrocyte acetylation was examined using immuno-
histochemical staining for acetylated histone H4. Intensely
positive staining for acetyl-histone H4 was observed in the
chondrocytes of the cartilage obtained from the TSA 2.0
group. The population of acetyl-histone H4-positive chon-
drocytes in the cartilage obtained from the TSA 2.0 group
was signiﬁcantly higher than from the control group (Fig. 5).RT-PCR AND QUANTITATIVE REAL-TIME PCRThe pro-inﬂammatory cytokine stimulation with IL-1b
(10 ng/ml) and TNF-a (1 ng/ml) and TSA treatment did not
affect the cell count and cell morphology of ATDC5 during
6 h of experimental period [Fig. 6(A)]. At the present exper-
imental period, treatment by TSA did not show signiﬁcant
catabolic effect on type II collagen and aggrecan
[Fig. 6(B)]. In contrast, MMPs were much more inﬂuenced
by cytokine stimulation than type II collagen and aggrecan.
Cytokine stimulation of the cells induced MMP-3 (31-fold)
and MMP-13 (7.4-fold) expression at 6 h, and co-incubation
with TSA (2 mM) signiﬁcantly down-regulated MMP-3 mRNA
expression (P< 0.05) and showed the tendency to down-
regulate the MMP-13 expression (not signiﬁcant)
[Fig. 6(C)]. The experiments were done at least three times
and generated similar results.Discussion
MMPs play a central role in cartilage breakdown by de-
grading type II collagen and aggrecans, which are major
components of the ECM of articular cartilage17. Chondro-
cytes are also involved in cartilage breakdown by secreting
high amounts of MMPs in conditions of arthritis18. Although
several strategies have been designed to develop effective
inhibitors that prevent the expression and activation of MMP
within the joints, no effective clinical agents have yet been
reported. In the current study, the in vivo effect of HDAC
inhibitors on chondrocyte expression of MMPs in CAIA
mice was examined. It was demonstrated that TSA amelio-
rated the clinical arthritis score and the degree of joint in-
ﬂammation, as well as the amount of cartilage destruction,
in a dose-dependent manner. Chondrocyte expression of
MMP-3 and MMP-13, which may play a prominent role in
cartilage destruction, was signiﬁcantly affected by TSA
treatment, as shown by the immunohistochemistry and
in vitro analysis. These ﬁndings suggest that modiﬁcation
of the chromatin structure of the key genes involved in the
pathogenesis of arthritis might play a beneﬁcial role in the
regulation of synovial inﬂammation and subsequent carti-
lage destruction in arthritis. The control of catabolic geneexpression by TSA may be, at least in part, a direct effect
of TSA on chondrocytes, as suggested by the up-regulation
of histone H4 acetylation after TSA treatment.
The precise mechanism that underlies the suppression of
MMP by HDAC inhibitors is still unknown. The expression
and production of MMPs are regulated by a variety of extra-
cellular signals via the transcriptional activation of cyto-
kines, growth factors, or matrix molecules2,11. Among the
pro-inﬂammatory cytokines, IL-1 plays a central role in the
induction of MMP-1, -3, -8, -13, and -1417. Our previous
study showed that FK228 inhibited IL-1b and TNF-a expres-
sion in the synovium of CAIA7. A similar effect on cytokine
expression was observed in human RA synovial ﬁbroblasts
(RASFs) treated with TSA in vitro (unpublished data). Thus,
it is reasonable to suggest that HDAC inhibitors indirectly
contribute to the suppression of cartilage destruction
through inhibition of the production and release of pro-
inﬂammatory cytokines from synovial tissue.
The activation of MMPs depends on signal transduction
pathways, mainly in the mitogen-activated protein (MAP)
kinase and I-kB pathway; this is followed by activation of var-
ious transcriptional factors, such as nuclear factor of acti-
vated T-cells (NFAT), signal transducer and activator of
transcription (STAT), nuclear factor kappaB (NF-kB), and ac-
tivator protein-1 (AP-1)11. These transcriptional factors offer
multiple therapeutic targets that should be investigated with
respect to their ability to protect cartilage from enzymatic
degradation19. Klampfer et al. demonstrated that STAT-
dependent transcription of interferon-gamma (IFN-g) was
inhibited by HDAC inhibitors, such as TSA butyrate and
suberoylanilide hydroxamic acid (SAHA), in colorectal carci-
noma cell lines20. The inhibition of NF-kB activity by HDAC
inhibitors was also recently reported in several cell
systems21,22. Moreover, the AP-1 binding site is present in
the promoter region of all MMPs, except for MMP-2, which
suggests jun/fos transcription factor binding plays a central
role17. HDAC inhibitors reportedly block the induction of
c-jun transcription by inhibiting the recruitment of the pre-
initiation complex (RNApolymerase II and transcription factor
IIB (TFIIB)) to the c-jun promoter23. These facts suggest that
HDAC activity might be involved in multiple steps within the
MMP activation pathways, and that its inhibition by HDAC
inhibitors may reduce chondrocyte MMP expression in
CAIA mice.
Importantly, the biological activity of MMP is balanced via
the inhibition of active enzymes by TIMP, which form a stable
and irreversible equimolar complex24. In arthritis model
mice, TIMP-1, showing a similar expression proﬁle to that
of MMP-3, was highly expressed during the acute phases
of arthritis25. However, the amount of TIMPs that was pres-
ent was insufﬁcient to suppress MMPs’ activity under the
conditions of arthritis26,27. Pelletier et al. demonstrated that
IL-1 signiﬁcantly decreased TIMP-1 synthesis in OA and
RA culture cartilage explants, whereas the synthesis of
MMPs was increased28. Yoshihara et al. reported that
MMPs/TIMPs ratios were higher in RA than OA, and that
they were correlated to degrading activity. They concluded
that the local imbalance of MMPs to TIMPs may contribute
to cartilage destruction29. In this regard, it has been sug-
gested that the delivery of functional TIMPs’ genes may re-
sult in the inhibition of cartilage degradation. A recent report
showed that TIMP-1-transduced cartilage resists the cata-
bolic effects of IL-1, and has reduced MMP activity, as well
as decreased loss of type II collagen30. In the current study,
we did not examine whether the amount that TIMP-1 was up-
regulated by TSA treatment was sufﬁcient to block cartilage
MMPs activity. However, the down-regulation of MMPs
Fig. 4. Immunohistochemical staining of MMP-3, MMP-13, and TIMP-1 in joint cartilage. The number of MMP-3 and MMP-13-positive chon-
drocytes was signiﬁcantly lower in the TSA 2.0 mg/kg group (n¼ 5) than in the control group (n¼ 5). In contrast, TIMP-1 was strongly ex-
pressed in the joint cartilage obtained from the TSA 2.0 mg/kg group. The population of TIMP-1-positive chondrocytes was signiﬁcantly
higher in the TSA 2.0 mg/kg group than in the control group. Representative immunohistochemistry results are shown in the upper panels.
Error bars express SD (*P< 0.01, **P< 0.001 by ManneWhitney U test).
Fig. 5. Immunohistochemical staining for acetyl-histone H4. Cartilage specimens obtained from the control and TSA 2.0 mg/kg groups (n¼ 5
each) were positive for acetyl-histone H4 (left panels). The number of acetyl-histone H4-positive cells was higher in the TSA 2.0 mg/kg group
than in the control group. Error bars express SD (*P< 0.05 by ManneWhitney U test).
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noted in the chondrocytes of TSA-treated CAIA; this indi-
cates that the inhibition of HDAC activity might lead to amod-
iﬁcation of chondrocyte gene expression, which results in
the correction of the imbalance between MMPs and TIMPs.
The direct effect of HDAC inhibitors on cytokine-induced
chondrocyte gene expression was ﬁrst demonstrated by
Young et al.12. They reported that the IL-1a/oncostatin M
(OSM)-induced expression of MMP-1, -13, ADAMTS-4, -5,
and -9 was suppressed by TSA in human chondrosarcoma
cell line and human articular chondrocytes. Thus, we con-
sidered that the control of catabolic gene expression by
TSA seen in the present study may be, at least in part, a di-
rect effect TSA on chondrocytes. As the change in histone
H4 acetylation in chondrocytes from TSA-treated animals
seen in the present study was only moderate (from 20 to
30% positive chondrocytes), and could not account for the
observed TSA-induced chondro-protective effect of TSA,
we performed the in vitro assay using ATDC5 to examine
whether TSA directly affects the chondrocyte gene expres-
sion. In our in vitro experimental protocol, the treatment byTSA did not show the signiﬁcant suppressive effect on type
II collagen and aggrecan mRNA expression. In contrast, it
was demonstrated that pro-inﬂammatory cytokine-induced
MMP-3 mRNA expression was signiﬁcantly down-regulated
by TSA treatment in murine chondrogenic ATDC5 cells. On
the other hand, the expression of pro-inﬂammatory cyto-
kine-induced MMP-13 was likely to be reduced by TSA
treatment, but not signiﬁcantly. This discrepancy with the re-
sults of previous study12 might be due to the difference of
stimulation, incubation time with TSA, and cell type used.
However, these results cumulatively suggest that TSA
might exert the chondro-protective effect not only by sup-
pression of synovitis, but also by directly modulating the
gene expressions of chondrocytes.
Finally, in this study, it was found that daily administration
of TSA successfully ameliorated the clinical arthritis seen in
the mouse CAIA model in a dose-dependent manner. The
TSA-treated groups had signiﬁcantly less histological joint
inﬂammation and cartilage destruction. Immunohisto-
chemical study showed that, compared to controls, there
was a signiﬁcant down-regulation of MMPs expression,
AB
C
Fig. 6. Effect of pro-inﬂammatory cytokine and TSA on the morphology and gene expression of murine ATDC5 chondrogenic cells. (A) Mor-
phologic features of ATDC5 cells examined by phase-contrast microscopy. No differences were observed in the TSA-treated cells compared
with non-stimulated or cytokine-stimulated cells. Original magniﬁcation: 200. (B) The effect of cytokine stimulation and TSA treatment on the
expression of type II collagen (Col2a1), aggrecan examined by RT-PCR. TSA did not show the signiﬁcant catabolic effect on type II collagen
and aggrecan expression. (C) The effect of cytokine stimulation and TSA treatment on the expression of MMP-3 and -13 mRNA by ATDC5
examined by real-time PCR. Cytokine-induced expression of MMP-3, but not MMP-13 was signiﬁcantly suppressed by TSA treatment. All
values are averages in triplicated tests. Error bars express SD (*P< 0.05 by ManneWhitney U test, n.s.: not signiﬁcant).
731Osteoarthritis and Cartilage Vol. 16, No. 6up-regulation of TIMP-1 expression, and hyperacetylation in
the joint cartilage chondrocytes of the TSA-treated groups.
In vitro examination demonstrated that TSA down-regulated
the pro-inﬂammatory cytokine-induced MMP-3 mRNA
expression in chondrocytes without showing the suppressive
effect of type II collagen and aggrecan gene expressions.
The precise mechanism that underlies the regulation of
chondrocyte gene expression by HDAC inhibitors remains
unknown. However, our results suggest that HDAC inhibi-
tors may have a direct inhibitory effect on cartilage destruc-
tion in inﬂammatory arthritis.Conﬂict of interest
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